Nick Paul Taylor
In this week's EuroBiotech Report, GW Pharmaceuticals is once again turning to U.S. investors to fuel the advance of its cannabis-based pipeline. The latest offering ...
When Vyvanse in February won the FDA's first-ever approval for binge eating disorder (BED), Shire predicted the indication could help the med rake ...
Amgen's regulatory team for talimogene laherparepvec (T-Vec) was grilled by a group of outside FDA experts who picked up on some major questions regarding ...
After departing from Sanofi last year for the CEO's chair at Synta Pharmaceuticals, Anne Whitaker is now moving on to Valeant, where she'll step into the role ...
The cascade of venture cash into CRISPR-Cas9 startups is continuing with no end in sight, despite a patent brawl brewing over who owns the technology. Today it's CRISPR ...
Mylan is recalling 8 lots of injectable cancer drugs, most of them manufactured for Pfizer, after particulate was discovered in vials.
Just hours after Bristol-Myers Squibb beat Wall Street expectations with earnings that got a goose from antipsychotic Abilify, the FDA opened the floodgates to generics ...
Wednesday's a big day for Amgen, whose dual-acting cancer vaccine/viral therapy is coming up for review by an FDA panel of experts.
Despite all the excitement over Biogen's recent Phase I success in Alzheimer's, the question of whether attacking protein buildups in the brain can in fact treat ...
Novo Nordisk says its new drug Saxenda has a niche in the U.S. obesity market. Now, the Danish drugmaker has the chance to prove it. Saxenda is rolling out ...
Maryland biotech MaxCyte is delving into the world of CAR-T treatments for cancer, teaming up with Johns Hopkins University on a preclinical program.